Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1993 Nov 20;307(6915):1322–1325. doi: 10.1136/bmj.307.6915.1322

Cost effectiveness analysis of early zidovudine treatment of HIV infected patients.

E Z Oddone 1, P Cowper 1, J D Hamilton 1, D B Matchar 1, P Hartigan 1, G Samsa 1, M Simberkoff 1, J R Feussner 1
PMCID: PMC1679458  PMID: 8257887

Abstract

OBJECTIVE--To compare cost effectiveness of early and later treatment with zidovudine for patients infected with HIV. DESIGN--Markov chain analysis of cost effectiveness based on results of use of health care and efficacy from a trial of zidovudine treatment. SETTING--Seven Veterans Affairs medical centres in the United States. SUBJECTS--338 patients with symptomatic HIV infection and a lymphocyte count of 200 x 10(6) to 500 x 10(6) CD4 cells/l. INTERVENTIONS--Zidovudine 1500 mg/day started either at recruitment to the trial or when CD4 cell count fell below 200 x 10(6)/l. MAIN OUTCOME MEASURES--Health care costs and rates of disease progression between six clinical states of HIV infection. RESULTS--Patients given early treatment with zidovudine remained without AIDS for an extra two months at a cost of $10,750 for each extra month without AIDS (at 1991 costs). Cost effectiveness ratio was most sensitive to the cost of zidovudine and to the quality of life of patients receiving early treatment. At treatment of 500 mg/day the cost effectiveness ratio for early treatment was $5432 for each extra month without AIDS. Patients given early treatment experienced more side effects, and if their quality of life was devalued by 8% compared with patients treated later the two treatments were equivalent in terms of quality adjusted months of life without AIDS. CONCLUSIONS--Early treatment with zidovudine is expensive and is very sensitive to the cost of zidovudine and to potential reductions in quality of life of patients who experience side effects. Doctors should reconsider early treatment with zidovudine for patients who experience side effects that substantially compromise their quality of life.

Full text

PDF
1322

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  2. Beck J. R., Pauker S. G. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419–458. doi: 10.1177/0272989X8300300403. [DOI] [PubMed] [Google Scholar]
  3. Evans R. W. Cost-effectiveness analysis of transplantation. Surg Clin North Am. 1986 Jun;66(3):603–616. doi: 10.1016/s0039-6109(16)43943-5. [DOI] [PubMed] [Google Scholar]
  4. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  5. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  6. Garner T. I., Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care. 1987 Jan;25(1):25–34. doi: 10.1097/00005650-198701000-00004. [DOI] [PubMed] [Google Scholar]
  7. Gelber R. D., Lenderking W. R., Cotton D. J., Cole B. F., Fischl M. A., Goldhirsch A., Testa M. A. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. Ann Intern Med. 1992 Jun 15;116(12 Pt 1):961–966. doi: 10.7326/0003-4819-116-12-961. [DOI] [PubMed] [Google Scholar]
  8. Graham N. M., Zeger S. L., Park L. P., Phair J. P., Detels R., Vermund S. H., Ho M., Saah A. J. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet. 1991 Aug 3;338(8762):265–269. doi: 10.1016/0140-6736(91)90414-k. [DOI] [PubMed] [Google Scholar]
  9. Graham N. M., Zeger S. L., Park L. P., Vermund S. H., Detels R., Rinaldo C. R., Phair J. P. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992 Apr 16;326(16):1037–1042. doi: 10.1056/NEJM199204163261601. [DOI] [PubMed] [Google Scholar]
  10. Hamilton J. D., Hartigan P. M., Simberkoff M. S., Day P. L., Diamond G. R., Dickinson G. M., Drusano G. L., Egorin M. J., George W. L., Gordin F. M. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992 Feb 13;326(7):437–443. doi: 10.1056/NEJM199202133260703. [DOI] [PubMed] [Google Scholar]
  11. Koch M. A., Volberding P. A., Lagakos S. W., Booth D. K., Pettinelli C., Myers M. W. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med. 1992 Nov;152(11):2286–2292. [PubMed] [Google Scholar]
  12. Lubeck D. P., Fries J. F. Health status among persons infected with human immunodeficiency virus. A community-based study. Med Care. 1993 Mar;31(3):269–276. doi: 10.1097/00005650-199303000-00008. [DOI] [PubMed] [Google Scholar]
  13. Moore R. D., Hidalgo J., Sugland B. W., Chaisson R. E. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991 May 16;324(20):1412–1416. doi: 10.1056/NEJM199105163242006. [DOI] [PubMed] [Google Scholar]
  14. Schulman K. A., Lynn L. A., Glick H. A., Eisenberg J. M. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 May 1;114(9):798–802. doi: 10.7326/0003-4819-114-9-798. [DOI] [PubMed] [Google Scholar]
  15. Swanson C. E., Cooper D. A. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group. AIDS. 1990 Aug;4(8):749–757. doi: 10.1097/00002030-199008000-00006. [DOI] [PubMed] [Google Scholar]
  16. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
  17. Weeks J. C., Tierney M. R., Weinstein M. C. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991 Jul 11;325(2):81–86. doi: 10.1056/NEJM199107113250202. [DOI] [PubMed] [Google Scholar]
  18. Welch H. G., Larson E. B. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 1989 Sep 21;321(12):807–812. doi: 10.1056/NEJM198909213211207. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES